TY - JOUR
T1 - A Phase Ib/II Study of the BRAF Inhibitor Encorafenib plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors
AU - Sullivan, Ryan J.
AU - Weber, Jeffrey
AU - Patel, Sapna
AU - Dummer, Reinhard
AU - Carlino, Matteo S.
AU - Tan, Daniel S.W.
AU - Lebbe, Celeste
AU - Siena, Salvatore
AU - Elez, Elena
AU - Wollenberg, Lance
AU - Pickard, Michael D.
AU - Sandor, Victor
AU - Ascierto, Paolo A.
N1 - Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Purpose: This open-label, dose-finding phase Ib/II study reports the safety and activity of the first combination use with BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with BRAF V600E–mutant solid tumors. Patients and Methods: In phase I, the recommended phase 2 doses (RP2D) were established (primary objective). In phase II, the clinical activity of the combination at the RP2D was assessed (primary objective) in patients with BRAF-mutant metastatic colorectal cancer (mCRC), BRAFi-treated BRAF-mutant melanoma, and BRAFi-naïve BRAF-mutant melanoma. Results: A total of 126 patients with BRAF-mutant solid tumors were enrolled (phase I: 47 patients; phase II: 79 patients). The RP2D was encorafenib 450 mg once daily plus binimetinib 45 mg twice daily and pharmacokinetic data suggest that drug exposures of each agent were similar in combination compared with single-agent studies. In the phase II cohorts, confirmed responses were seen in two of 11 (18%) evaluable patients with mCRC, 11 of 26 (42%) evaluable patients with BRAFi-pretreated melanoma, and 28 of 42 (67%) BRAFi-naïve patients with melanoma. The most common grade 3/4 adverse event in phase II was increased alanine aminotransferase. Conclusions: The combination of encorafenib (450 mg) plus binimetinib (45 mg) showed acceptable tolerability and encouraging activity in patients with BRAF V600–mutant tumors, which led to the dose selection for the melanoma COLUMBUS study. The safety profile of the combination was consistent with other approved BRAFi plus MEKi regimens, with several differences, including lower rates of dose-limiting pyrexia, arthralgia, and photosensitivity.
AB - Purpose: This open-label, dose-finding phase Ib/II study reports the safety and activity of the first combination use with BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with BRAF V600E–mutant solid tumors. Patients and Methods: In phase I, the recommended phase 2 doses (RP2D) were established (primary objective). In phase II, the clinical activity of the combination at the RP2D was assessed (primary objective) in patients with BRAF-mutant metastatic colorectal cancer (mCRC), BRAFi-treated BRAF-mutant melanoma, and BRAFi-naïve BRAF-mutant melanoma. Results: A total of 126 patients with BRAF-mutant solid tumors were enrolled (phase I: 47 patients; phase II: 79 patients). The RP2D was encorafenib 450 mg once daily plus binimetinib 45 mg twice daily and pharmacokinetic data suggest that drug exposures of each agent were similar in combination compared with single-agent studies. In the phase II cohorts, confirmed responses were seen in two of 11 (18%) evaluable patients with mCRC, 11 of 26 (42%) evaluable patients with BRAFi-pretreated melanoma, and 28 of 42 (67%) BRAFi-naïve patients with melanoma. The most common grade 3/4 adverse event in phase II was increased alanine aminotransferase. Conclusions: The combination of encorafenib (450 mg) plus binimetinib (45 mg) showed acceptable tolerability and encouraging activity in patients with BRAF V600–mutant tumors, which led to the dose selection for the melanoma COLUMBUS study. The safety profile of the combination was consistent with other approved BRAFi plus MEKi regimens, with several differences, including lower rates of dose-limiting pyrexia, arthralgia, and photosensitivity.
UR - http://www.scopus.com/inward/record.url?scp=85101335000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101335000&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-3550
DO - 10.1158/1078-0432.CCR-19-3550
M3 - Article
C2 - 32669376
AN - SCOPUS:85101335000
SN - 1078-0432
VL - 26
SP - 5102
EP - 5112
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 19
ER -